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Accurate determination of human epidermal growth factor receptor 2 (HER2) status is critical for opti-
mizing breast cancer outcomes. In 2007, the American Society of Clinical Oncology (ASCO) and the Col-
lege of American Pathologists (CAP) developed guidelines for HER2 testing to reduce inaccuracy.
However, current ASCO/CAP criteria may restrict access to HER2-targeted therapy for some patient
groups who would derive a clear clinical beneﬁt. ASCO/CAP are currently reviewing their guidelines to
further optimize HER2 testing and include emerging techniques. Guidelines are critical for optimizing
care, as is ongoing research into techniques that accurately and reproducibly assess HER2 status.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-SA license.Introduction
The human epidermal growth factor receptor 2 oncogene
(ERBB2, HER2, or neu) encodes the type I receptor tyrosine kinase
HER2. HER2 is an oncogene, with signiﬁcant homology to HER1/
HER3 and HER4, which drives proliferation, migration, and invasion
in breast cancer [1]. The HER2 gene is ampliﬁed in approximately
15–20% of breast cancers [1,2] and gene ampliﬁcation is closely
linked to overexpression of the HER2 protein. From a clinical per-
spective, tumors with normal HER2 levels are referred to as either
‘‘HER2-normal’’ or ‘‘HER2-negative’’ (lacking HER2 overexpression/
ampliﬁcation), while tumors with gene ampliﬁcation/overexpres-
sion are referred to as ‘‘HER2-positive’’. Prior to the availability of
HER2-directed therapies, HER2-positive breast cancer was associ-
ated with worse prognosis compared with HER2-normal breastcancer, including higher mortality in early-stage disease, reduced
time to relapse, and an increased incidence of metastases [3–5].
The HER2-targeted agents trastuzumab, lapatinib, pertuzumab,
and trastuzumab emtansine have signiﬁcantly improved clinical
outcomes in patients with HER2-positive breast cancer in the met-
astatic and adjuvant settings [6–13]. Accurate determination of
HER2 status is therefore critical to optimizing clinical outcomes
in patients with breast cancer.
HER2 status is most commonly determined using immunohis-
tochemistry (IHC) or ﬂuorescence in situ hybridization (FISH).
IHC assesses the expression of the HER2 protein in cell membranes,
and FISH assesses HER2 gene ampliﬁcation [14].
The suboptimal performance and interpretation of IHC and FISH
assays is a source of inaccuracy in HER2 testing. Moreover, differ-
ences in HER2 testing methods, interpretation, and reporting crite-
ria exist, which can create uncertainty for oncologists when
determining patient eligibility for treatment. In 2007, the American
Society of Clinical Oncology (ASCO) and the College of American
Pathologists (CAP) developed guidelines for the conduct and inter-
pretation of HER2 testing in an attempt to reduce the potential for
variability between laboratories [14]. These guidelines include
thresholds for HER2 protein expression by IHC and for gene copy
ratios by FISH that differ from those recommended by the United
States Food and Drug Administration (FDA)–approved test kits,
which led to some confusion when determining patient eligibility
for treatment.
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ment of HER2 testing, describe the potential sources of variation in
the reporting of HER2 status in clinical practice, describe the devel-
opment and impact of the ASCO/CAP HER2 testing guidelines on
the identiﬁcation of patients eligible for treatment, evaluate
whether these guidelines have optimized the assessment and
reporting of HER2 status in patients with breast cancer, and iden-
tify ways in which HER2 testing techniques are evolving and how
this may impact future practice.Development of HER2 testing
One of the key challenges in the early development of diagnos-
tic assays to assess HER2 status was the lack of a recognized abso-
lute ‘‘gold standard’’ measure of HER2 expression/gene
ampliﬁcation against which to benchmark the accuracy, validity,
and bias of methods now widely used in diagnostic laboratories.
The initial preclinical studies of trastuzumab used a cocktail of
two mouse monoclonal antibodies, which was used in the Clinical
Trials Assay (CTA) to assess HER2 status in the pivotal trastuzumab
clinical trials [6,7]. Since the development of the CTA, a number of
commercially available testing kits have received approval from
the FDA for the assessment of patients for whom trastuzumab
may be a suitable treatment (Table 1) [15]. These include four
IHC tests, two FISH assays, and three colorimetric ISH assays (see
Table 1).Immunohistochemistry tests
Grading of IHC assays is based on a 0, 1+, 2+, and 3+ scoring sys-
tem. According to the package inserts of IHC assays, tumor speci-
mens that demonstrate strong complete membrane staining in
>10% of tumor cells are classiﬁed as 3+ on IHC and constitute an
unequivocal positive result [16,17] in line with the eligibility crite-
ria for the pivotal trastuzumab trials [6,7]. Specimens showing
weak-to-moderate staining in >10% of tumor cells are scored 2+
[16,17] and regarded as equivocal, requiring conﬁrmation of
HER2 status by an alternative method, usually ISH.
The HercepTest™ (Dako, Glostrup, Denmark and Carpinteria,
CA), an IHC test approved by the FDA at the same time as trast-
uzumab, uses a rabbit polyclonal antibody against HER2. The con-
cordance between CTA and HercepTest was 79% [16]. Despite the
initial concerns this created, the HercepTest went on to demon-
strate clinically useful results in key parameters of assay perfor-
mance; in the package insert [16], it is reported to have
speciﬁcity of 100%, sensitivity of 70%, and (critically) accuracy of
85% to 89% when compared with samples proven by multiple alter-
native methods to demonstrate both HER2 gene ampliﬁcation and
HER2 protein overexpression [18].Table 1
FDA-approved HER2 testing kits indicated as aids in the assessment of patients for whom
Assay type Trade name
Semi-quantitative IHC HercepTest™
IHC PATHWAY
IHC InSite
Semi-quantitative IHC Bond Oracle™
FISH PathVysion
FISH PharmDx™ Kit
CISH SPoT-Light
CISH INFORM HER2 dual ISH DNA probe cocktail
CISH PharmDx™
CISH, chromogenic in situ hybridization; FDA, US Food and Drug Administration; FISH, ﬂ
IHC, immunohistochemistry; ISH, in situ hybridization.Two other FDA-approved IHC systems in widespread use are the
Pathway anti-HER2/neu test (Ventana Medical Systems Inc., Tuc-
son, AZ), which utilizes a rabbit monoclonal antibody (4B5), and
the Bond Oracle™ HER2 IHC System (Leica Biosystems, Newcastle
upon Tyne, UK), which uses the mouse CB11 clone. For the Path-
way anti-HER2/neu test, originally the mouse CB11 clone was
used [17], but this was changed in 2008 to the 4B5 antibody
[19]. The effectiveness of this newer test was based on concordant
results with the CB11 clone. The overall level of agreement be-
tween the CB11 and 4B5 clones based on pathologists’ assessment
ranges from 83% to 96% [17,20].
ISH tests
Initially, the FDA approved HER2 FISH assays for the identiﬁca-
tion of women with node-negative disease at high risk of recur-
rence or disease-related death, or for selection to doxorubicin
chemotherapy [18]. However, this utility was expanded in 2001
when the HER2 FISH PathVysion Kit (Abbott Molecular, Des
Plaines, IL) gained approval as an aid in the assessment of patients
for whom trastuzumab treatment was being considered [15].
Based on the product information, and in line with eligibility crite-
ria for the pivotal adjuvant trastuzumab trials [8,9,11], a FISH-po-
sitive result is deﬁned as a HER2/CEP17 ratio P2.0. Other
commercial FISH and chromogenic in situ hybridization (CISH)
tests have also since gained FDA approval for this indication (see
Table 1).
HER2 FISH testing was approved based on the high rate of con-
cordance reported between the IHC CTA and FISH assays of 82%
[21]. In a recently published round-robin study evaluating HER2
testing of 389 tumor blocks from three large adjuvant trials (North
Central Cancer Treatment Group [NCCTG] N9831, Breast Cancer
International Research Group [BCIRG]-006, and BCIRG-005) per-
formed at the three separate central laboratories, the overall con-
cordance between the IHC and FISH results was even higher, at
92% [22].
When measured against an external ‘‘gold standard’’ molecular
characterization of HER2 status, FISH is more accurate, reproduc-
ible, and robust than IHC [18]. However, for practical and historical
reasons, IHC has been more widely used as the primary test for
HER2 status. IHC was the assay originally used in clinical trials. It
is comparatively quick, results can be viewed using a conventional
bright-ﬁeld microscope, and stained tissues do not degrade over
time [23]. Furthermore, IHC testing permits parallel viewing of tu-
mor cell morphological features. FISH is technically more demand-
ing, was largely unfamiliar to pathologists during the
implementation of HER2 testing, and requires the use of ﬂuores-
cence microscopy [23]. As will be discussed, the potentially greater
accuracy of FISH relative to IHC does not mean that a patient test-
ing positive on IHC, but negative on FISH, should not be consideredHER2-targeted treatment is being considered [15].
Manufacturer Date of FDA approval
DAKO September 1998
Ventana Medical Systems Inc November 2000
Biogenex Laboratories Inc December 2004
Leica Biosystems April 2012
Abbott Molecular Inc December 2001
DAKO May 2005
Life Technologies Inc July 2008
Ventana Medical Systems Inc June 2011
DAKO November 2011
uorescence in situ hybridization; HER2, human epidermal growth factor receptor 2;
278 E.A. Perez et al. / Cancer Treatment Reviews 40 (2014) 276–284ineligible for HER2-speciﬁc therapy. Each test detects a distinct cel-
lular trait (elevated protein levels versus ampliﬁed DNA se-
quences), and may potentially reveal HER2-positive cases that
are overlooked by the other.
Emerging technologies for HER2 testing include CISH and
silver-enhanced in situ hybridization (SISH). CISH uses a peroxidase
enzyme-labeled probe for chromogenic detection by diaminobenzi-
dine, while SISH uses the same systemwith a silver-based detection
system. Because these processes do not involve ﬂuorescent dye, a
standard bright-ﬁeld microscope can be used, thereby circumvent-
ing many of the perceived disadvantages of FISH [23]. Automated
ISH techniquesmay enablemore rapid screening of patient samples
than manual FISH. CISH results can be stored because the signal is
stable [23]. In 2008, the FDA approved the SPoT-Light Kit (Invitro-
gen/Life Technologies, Grand Island, NY), the ﬁrst CISH assay for
HER2 testing [15]. This was followed by the HER2 CISH pharmDx™
Kit (Dako, Glostrup, Denmark and Carpinteria, CA) in 2011 [15].
Scoring of gene ampliﬁcation for the SPoT-Light kit was initially
very simple but has evolved to allow deﬁnition of no, low, and high
ampliﬁcation states [23]. A SISH assay (INFORM HER2 Dual ISH As-
say, Ventana Medical Systems, Tucson, AZ) has also been approved
by the FDA [15].
Studies show very high concordance rates between CISH, SISH,
and FISH; 96% for CISH/SISH, 81% to 100% for CISH/FISH, and 94% to
98% for SISH/FISH [23–28]. SISH is fully automated, comparatively
quick to perform, and, similar to CISH, does not require the use of a
specialized microscope [23]. An additional emerging technology is
dual-color, dual-hapten, brightﬁeld in situ hybridization (DDISH).
DDISH has all of the advantages of SISH (e.g., it is fully automated
and evaluable with conventional microscopy) but with one impor-
tant difference. In contrast to SISH, which requires two separate
slides to detect both HER2 and CEP17, DDISH uses double-stranded
probes labeled with two haptens to detect both markers on a single
slide. Although data are limited at present, the concordance rate
between DDISH and FISH appears to be high [28,29].
Existing evidence (see previous paragraph) would suggest that,
if adequately controlled, there is minimal difference between dif-
ferent ISH approaches to determination of HER2 gene ampliﬁcation
(by FISH, CISH, SISH, or DDISH). Some national guidelines reﬂect
this at present [30]. However, although the use of newer testing
technologies is becoming more commonplace, the existing ASCO/
CAP guidelines (from 2007) predominantly recommend HER2 test-
ing by IHC or FISH [14], with CISH brieﬂy recommended as an
alternative to FISH in cases of equivocal IHC test results. Future up-
dates to these guidelines, expected in 2013 or 2014, may incorpo-
rate more comprehensive recommendations for CISH and provide
new guidance for SISH and DDISH.Sources of variability in HER2 testing
Variability in HER2 testing can arise from pre-analytic, analytic,
and post-analytic factors. The relevance of these factors varies
according to the testing method (e.g., IHC vs. FISH) but each may
affect the accuracy, reliability, and reproducibility of results.Pre-analytic factors
Pre-analytic factors relate mainly to tissue sample handling
[14], and are considered to have less impact with techniques based
on gene ampliﬁcation, since DNA is more stable than protein. That
said, data relating to pre-analytic factors affecting FISH and the
other gene ampliﬁcation methodologies are lacking.
The time to ﬁxation, i.e., the time between biopsy or resection
and placing the sample in ﬁxative, should be as short as possible.
The duration of ﬁxation has a large impact on results and is a majorsource of variability. For IHC, a minimum ﬁxation period of 6–8 h
has been suggested and ASCO/CAP guidelines recommend that ﬁx-
ation does not exceed 48 h [15,31]. The critical nature of the min-
imum ﬁxation period depends on the type of biopsy obtained;
small biopsies and core samples are vulnerable to receiving insuf-
ﬁcient initial formaldehyde ﬁxation, which can result in inconsis-
tencies in tissue antigen demonstration [31].
Tissue processing methods can also vary widely. The ASCO/CAP
guidelines recommend recording information related to these pre-
analytic factors (such as time to ﬁxation and duration of ﬁxation)
as standard procedure [14]. The guidelines also state that if stan-
dard conditions are altered for routine use in any way, e.g. using
microwave ﬁxation, alternative ﬁxatives, etc., these must ﬁrst be
validated against standard procedures [14].
Analytic factors
Analytic factors associated with the assay can have a substantial
impact on the consistency of results within and between laborato-
ries. Technical validation of assays is a mandatory requirement for
laboratories, including for ‘‘home brew’’ tests that need to be vali-
dated in the United States under the Clinical Laboratory Improve-
ment Amendment [14]. The guidelines state that concordance of
95% to a validated FISH assay is sufﬁcient [14]. However, if the pre-
vious assay was similarly validated to an existing assay, each vali-
dation step of 95% concordance could take an assay further from
the actual or desirable validation point [32].
The regular calibration of microscopes and the use of standard-
ized laboratory procedures, along with continual professional
development and dedicated training programs for personnel, are
critical to reducing variability [14]. The ASCO/CAP guidelines rec-
ommend that deviation from such standards should be recorded
and justiﬁed by revalidation [14].
Formalin typically masks antigenic epitopes, necessitating anti-
gen retrieval steps to allow them to be detected by antibodies
[14,31]. The type of antigen retrieval, as well as factors such as
microwave kinetics and the chemical composition of the retrieval
solution, can have a large impact on tissue staining patterns
[14,31].
Compared with manual techniques, automated immunostain-
ing methods have been suggested by ASCO/CAP and other experts
to reduce variability associated with technical factors [14,33].
However, automation cannot overcome all of these factors; even
with automated staining there can be daily variation in optical
density as high as 30% in the same tissue block [31].
Post-analytic factors
Post-analytic factors relate to interpretation of assay ﬁndings,
image analysis, reporting, and ongoing quality assurance [14].
Interpretation and cutoff values are a major source of variability
both within and between laboratories [31]. Assessing parameters
for IHC scoring is very much inﬂuenced by the observer and includ-
ing a positive control showing different levels of staining with each
batch may reduce observer subjectivity [33]. The 0–3+ scoring sys-
tem used to assess HER2 immunostaining differs from scoring sys-
tems (e.g., H-score and Allred score) used to deﬁne cutoffs with
other IHC markers [33]. Interpretation is usually performed manu-
ally and results can vary depending on the experience and alert-
ness of the observer [33]. Scoring with FISH and newer HER2
testing techniques is generally more objective and quantitative
than with IHC [23].
Image analysis has been proposed as a means of improving the
objectivity of IHC interpretation and reducing interobserver vari-
ability [33]. However, image analysis is also susceptible to variabil-
ity based on the color-separation technique, the shutter speed, and
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sis is susceptible to inaccuracies from the amount of nuclear mate-
rial in the tissue sample and associated non-linearities in
absorption that occur at higher levels between the amount of nu-
clear material and intensity [31,33]. As a result, if image analysis
is used, the method must be validated and thresholds (positive,
equivocal, negative) deﬁned against samples with known FISH
ampliﬁcation levels [14]. Newer testing technologies often incor-
porate automated techniques to detect chromogenic signals, and
these are thought to improve efﬁciency and consistency, as well
as to provide high sample throughput and decrease the risk of error
[23].Genetic factors complicating HER2 test interpretation
At the advent of HER2 testing in metastatic breast cancer
(1999–2000) there was limited recognition of the molecular com-
plexity of breast cancer. Over the last 10–15 years, signiﬁcant
numbers of cases that are difﬁcult to interpret by either IHC or FISH
have been identiﬁed. These present a challenge to diagnosticians
and clinicians in selecting patients for HER2-directed therapy.
HER2 heterogeneity
Heterogeneous gene ampliﬁcation occurs when two or more
distinct or intermixed clones of cancer cells exhibit different pat-
terns of gene ampliﬁcation, i.e., areas of non-ampliﬁed and ampli-
ﬁed HER2. Studies in breast cancer have demonstrated cell-to-cell
heterogeneity of HER2 gene ampliﬁcation and HER2 protein
expression at highly variable rates of 1–50%, depending on the
methodologies and the sample set used [34–37]. The presence of
HER2 genetic heterogeneity can complicate IHC or FISH assessment
and lead to an inaccurate determination of HER2-directed therapy
suitability [34].
FISH uses two chromosome 17-speciﬁc probes to determine
ampliﬁcation of the HER2 gene based on the HER2/CEP17 ratio; a
locus-speciﬁc identiﬁer of HER2 and one speciﬁc for the a-satellite
DNA sequence at the centromere region. According to the 2007
ASCO/CAP guidelines, HER2/CEP17 ratios of >2.2 are considered
HER2-positive, whereas a ratio of 1.8–2.2 indicates an equivocal re-
sult, and samples with a ratio <1.8 are deemed HER2-normal [14].
A recent CAP publication deﬁned genetic heterogeneity as the pres-
ence of >5% and <50% of inﬁltrating tumor cells with HER2/CEP17
ratio >2.2 (when 20 cells are counted), or >5% and <50% of inﬁltrat-
ing tumor cells with >6 HER2 signals per cell using FISH [34].
However determined, molecular heterogeneity of HER2 gene
ampliﬁcation is recognized in at least 4–5% of breast cancers
[35,38] and could be more frequent in advanced disease. Most na-
tional guidelines recommend reporting HER2 ampliﬁcation status
separately for microscopically distinct tumor regions and using
this information in directing treatment choice [30].
HER2 status and disease progression
Genetic heterogeneity can also exist between the primary carci-
noma and metastases within the same patient [39]. Studies suggest
a range of ‘‘discordance’’ in ampliﬁcation/overexpression between
primary and distant sites up to approximately 50% in studies using
IHC, FISH, or both to evaluate HER2 status [40–43]. Most studies
show relatively low rates of discordance, suggesting that discrep-
ancies simply reﬂect interpretation difﬁculties [43]. However, the
studies that did show signiﬁcant levels of discordance included
those in which the proportion of cases with HER2 overexpression
increased or decreased in the distant tumor metastases relative
to the primary tumor. This suggests that HER2 ampliﬁcation andoverexpression can occur de novo in distant metastases in late-
stage disease, and that genetic divergence occurs at the time when
in situ cancers progress to invasive cancers [41]. As a result, HER2
guidelines increasingly recommend testing metastatic tumor
deposits, if biopsied, to direct treatment of patients with progres-
sive disease [30].‘‘Rogue’’ HER2 cases
Heterogeneous HER2 gene ampliﬁcation is not the only unusual
ISH pattern which causes interpretative challenges for patholo-
gists. Loss of chromosome 17 signals, co-ampliﬁcation of both
CEP17 and HER2 regions, as well as different patterns of heteroge-
neity, pose speciﬁc challenges in determining HER2 status, partic-
ularly in cases already identiﬁed as equivocal by IHC [38]. Since as
many as 10% of cases in a recent diagnostic audit (of more than
1700 cases) showed unusual ISH patterns [38], this is a growing
challenge. Focusing research on these uncommon, but not rare,
cases is essential to providing important assistance to clinicians
faced with diagnostic dilemmas. However, at present, clinicians
should be aware of the existence of these ‘‘rogue’’ cases and seek
expert advice to direct therapeutic choices.Evidence for variability
Discordance in HER2 results between local and central laborato-
ries participating in clinical trials has been well documented [44–
46]. Similar discordance has also been detected, albeit to a signiﬁ-
cantly lesser degree, between different central laboratories in the
round-robin analysis [22] (Table 2). When specimens from the
NCCTG N9831, BCIRG 005, and BCIRG 006 studies were analyzed
by three central laboratories, discordant results were recorded
for 30 specimens (8%) using either IHC or FISH [22]. Independent
adjudication led to consensus in 16 of 30 cases on IHC and 18 of
30 cases on FISH, resulting in an overall concordance rate of 96%
for IHC and 97% for FISH. Discordant ﬁndings mostly consisted of
samples that were borderline for HER2-positive status.
Compared with specimens reported as HER2-positive, discor-
dance between local and central laboratories appears to be lower
for the identiﬁcation of HER2-normal specimens. However, the
clinical implications of this form of discordance are still signiﬁcant
since inaccurate assignment of HER2-normal status leads to poten-
tially effective treatment being denied to patients for whom such
therapy is indicated. In the VIRGO observational cohort study of
patients with primarily HER2-normal breast cancer, discordance
between local and central laboratories was found in 21 of 499
specimens (4%) on IHC or FISH, such that specimens rated as
HER2-normal by local laboratories were found to be HER2-positive
centrally [47]. Based on this discordance rate, it was estimated
that, each year, more than 7000 patients in the United States and
more than 46,000 women globally would not receive HER2-tar-
geted therapy because of incorrect assignment of HER2 status by
local laboratories [47]. It is important to note that there is no evi-
dence that central testing is more accurate than local testing, sim-
ply that the results are discordant. In fact, 17 samples that were
centrally determined to be HER2-positive were initially locally as-
sessed with a single test. Of these, 9 were determined to be HER2-
positive with the testing methodology (IHC or FISH) not performed
initially. Therefore, when potentially ruling out the beneﬁts of a
HER2-speciﬁc treatment, reliance on a single negative test is not
advisable. Because of the inherent limitations of both IHC and FISH,
retesting of patients who are initially found to be HER2-negative
(by IHC or FISH), using the other type of test, may help ensure that
patients who would beneﬁt from HER2-targeted therapy are
identiﬁed.
Table 2
Interlaboratory concordance in HER2 status.
Reference Setting Specimens (N) Interlaboratory concordancea [n (%)]
IHC (HercepTest) FISH
Local vs. central comparisons
Paik et al. [44] NSABP B-31 104 82/104 (79%) 82/104 (79%)
Roche et al. [45] NCCTG N9831 119 81/110 (74%) 6/9 (67%)
Perez et al. [46] NCCTG N9831 2535 867/1063 (82%) 716/813 (88%)
Central vs. central comparisons
Perez et al. [22] NCCTG N9831, BCIRG 005, BCIRG 006 389 351/381 (92%) 343/373 (92%)
BCIRG, Breast Cancer International Research Group; FISH, ﬂuorescence in situ hybridization; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry;
NCCTG, North Central Cancer Treatment Group; NSABP, National Surgical Adjuvant Breast and Bowel Project.
a In local vs. central comparisons, this refers to the number of specimens graded as positive for HER2 by the local laboratory and conﬁrmed positive in central laboratory; in
the central vs. central comparison, this refers to the number of concordant results assessed by 3 pathologists at 3 central laboratories.
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cal laboratories regarding HER2-normal status was seen in 258 of
271 cases (95%) using FISH, and in 273 of 301 cases (91%) using
both IHC and FISH [46]. In the round-robin comparison of central
laboratories, all HER2-negative samples (n = 98) from the BCIRG
005 study and 57 of 59 (97%) samples from the NCCTG N9831
study were concordant among pathologists [22]. Although the
use of a central laboratory can limit the incidence of discordance,
it may not eradicate it, particularly for IHC which depends heavily
on pre-analytic steps, such as the collection and ﬁxation of speci-
mens, which often occur in a decentralized manner, in community
or academic pathology practices [32]. Given the uncertainties re-
vealed in all of these studies, a patient who tests HER2-positive
by one method but not another should be considered eligible for
HER2-speciﬁc therapy, whether the positive result derives from
IHC, FISH, or another method. By corollary, for patients initially
testing HER2-positive, there may be little utility in questioning
the result with a second test unless a speciﬁc reason exists to sus-
pect a false-positive.
Guidelines for optimal HER2 testing
The rationale for the ASCO/CAP guidelines of 2007 was to min-
imize the variance in HER2 test results seen in clinical practice
[14]. The guidelines put considerable emphasis on addressing
shortcomings in the pre-analytic, analytic, and post-analytic fac-
tors that contribute to variability [14], but included limited guid-
ance on choice of reagents.
The 2007 ASCO/CAP guidelines deﬁned HER2-positive status on
the basis of IHC 3+ (uniform intense staining of >30% of invasive tu-
mor cells) or FISH-positive (ratio of HER2 to CEP17 of >2.2 or aver-
age HER2 copy number >6 signals/nucleus) [14]. This differs from
the deﬁnition for HER2-positive status approved by the FDA, i.e.,
an IHC score of 3+, deﬁned as complete intense membrane staining
in >10% of cells, as deﬁned in the IHC package inserts. The rationale
for the change in IHC criteria from >10% staining to >30% staining
was based on the panel’s expert opinion that true IHC 3+ speci-
mens show a high percentage of strongly staining cells, but also
on their interpretation of data from studies with a cutoff of >10%
to deﬁne IHC 3+, and a desire to reduce the rate of false positive re-
sults in IHC [14]. Samples deemed equivocal with an IHC 2+ result
or strong complete staining of <30% (in the case of the ASCO/CAP
guidelines) are typically sent for conﬁrmatory (or reﬂex) testing
by FISH [14].
While previously, FISH results were deﬁned as normal or posi-
tive using a cutoff of HER2/CEP17 ratio of 2.0, the ASCO/CAP guide-
lines deﬁne positive status as a ratio of >2.2, normal as <1.8, and
equivocal as between 1.8 and 2.2 (or HER2 copy number of be-
tween four and six signals/nucleus if not using an internal control
probe). This was based on early reports on observer variability inHER2 ISH testing, although more recent studies suggest interob-
server variation is near to 5% and this covers both highly ampliﬁed
and non-ampliﬁed HER2 cases [28]. Assay consistency is improved
by counting more cells [30], which further reduces uncertainty in
these cases. Critically, changing the previously established criteria
for positivity was not intended to inﬂuence therapeutic decisions
and the 2007 ASCO/CAP guidelines speciﬁcally recommended
treatment of patients with HER2 ratios of 2.0 and above with
anti-HER2 therapies if deemed safe. The 2007 ASCO/CAP guidelines
also include the option of primary FISH testing [14], rather than
only recommending reﬂex FISH for equivocal IHC results, which
had been a common strategy in clinical practice. The latest UK
guidelines also recommend primary FISH testing for laboratories
wishing to do so [48] and extend this to other ISH methods, includ-
ing HER2 ISH for gastric cancer [30]. This is based on extensive evi-
dence supporting the use of ISH as a more robust, accurate, and
reproducible test for HER2 positivity. However, ASCO/CAP and
other guidelines still support a two-tier testing system.
Since the 2007 guidelines were published, ASCO/CAP has pub-
lished some revisions in recommended testing methodology relat-
ing to the optimal time from tissue acquisition to ﬁxation (i.e.,
must be 61 h and be recorded) and specimen handling [49], and
guidance on deﬁning genetic heterogeneity, as described previ-
ously [34].
Impact of the guidelines on HER2 testing
There is evidence to indicate that the ASCO/CAP guidelines have
not been fully implemented in US laboratories [50]. A survey con-
ducted late in 2008 indicated some inconsistency in using ASCO/
CAP scoring criteria to deﬁne HER2 status. Overall, 84% of laborato-
ries scored IHC specimens using the ASCO/CAP guidelines, but 13%
used the guidelines provided with the test kit and 3% used another
scoring guideline [50]. Approximately 70% of laboratories were
attempting to validate their procedures [50]. For example, 60% of
laboratories compared IHC and FISH results; of these, the 95% con-
cordance threshold was met by only 81% for HER2-normal ﬁndings
and by only 73% for HER2-positive ﬁndings [50].
While 85% of laboratories had changed their practices to ensure
that ﬁxation time guidelines were met, 14% had no speciﬁc policy
to address prolonged ﬁxation time and 28% did not record ﬁxation
times in their report [50]. However, more than 90% of laboratories
had active pathologist competency assessment processes in place
[50].
In laboratories where samples are being scored using the ASCO/
CAP recommended threshold of >30% of immunostained cells on
IHC, the rate of interobserver variability appears to have declined
[51], and the concordance with FISH has improved [52,53], causing
a lower incidence of false positive IHC results [54], consistent with
the guidelines’ intention. Similarly, Striebel and coworkers found
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for resampling and testing HER2 status in cancers that show an
equivocal result on initial FISH testing [55].
Other data, however, suggest that the guideline-prescribed
change in criteria used to deﬁne HER2-positive status may have
a negative impact on patient care by restricting access to HER2-tar-
geted treatment in patients who could beneﬁt from such treat-
ment. In a retrospective analysis, data from the NCCTG N9831
study of adjuvant chemotherapy ± trastuzumab were stratiﬁed
according to whether breast tumors met the 2007 ASCO/CAP crite-
ria for HER2-positive status by IHC and/or FISH, and compared clin-
ical outcomes from patients with these tumors to those with
tumors considered HER2-positive by FDA criteria but not by the
2007 ASCO/CAP criteria [56]. The effect of trastuzumab on dis-
ease-free survival was similar in both groups, with similar hazard
ratios (Fig. 1), although in the group deﬁned by FDA HER2-positive
criteria, the treatment effect fell short of statistical signiﬁcance
(likely because of the small number of patients) [56]. Applying
the ASCO/CAP IHC criteria to the 2904 patients rather than the
FDA criteria demonstrated that 4% of the tumors would not have
been considered HER2-positive. Based on this, more than 100 pa-
tients would have been excluded from potentially life-saving
HER2-targeted therapy, which can be extrapolated to 3000–5000
women annually in the United States [56].
Chibon and coworkers reported a similar ﬁnding using only the
FISH criteria for HER2 status. In their analysis of 108 samples of
invasive breast cancer tissue, HER2-positive status was reported
in 36 (33%) samples using the FDA criteria and in 32 (30%) samples
using ASCO/CAP 2007 criteria for HER2/CEP17 ratio [57]. Therefore,
four of the108 patients (4%) would have been eligible for HER2-tar-
geted therapy under the FDA guidelines but not under the ASCO/
CAP guidelines. Unfortunately, this study did not report the clinical
outcomes in these four patients. This study also identiﬁed discrep-
ancies between the HER2/CEP17 ratio and the HER2 copy number
criteria. All patients who had a HER2/CEP17 ratio ofP2 also had aFig. 1. DFS by treatment group in the NCCTG N9831 study in patients with HER2-positive
those with HER2-positive breast cancer by ASCO/CAP criteria (black lines). The asterisk ind
nodal involvement [56]. Reproduced from: Perez EA, et al. Predictability of adjuvant trastu
Cancer Inst. 2012;104:159–162, by permission of Oxford University Press. AC, doxorubicin
of American Pathologists; CI, conﬁdence interval; FDA, United States Food and Drug AdmHER2 copy number/nucleus >4, but nine of the 32 samples with a
HER2/CEP17 ratio of >2.2 did not have a HER2 copy number >6/nu-
cleus (ASCO/CAP criteria). Using the ASCO/CAP HER2 copy number
criteria would have resulted in only 26 patients being classiﬁed as
HER2-positive [57]. We therefore continue to support the use of
dual color (HER2/CEP17) ISH to determine HER2 gene ampliﬁcation
status.
Other researchers have suggested a cutoff HER2/CEP17 of 1.5
instead of the 2.2 recommended in ASCO/CAP or 2.0 approved by
the FDA [58], but clinical data to justify this cutoff are not available.
In contrast, some researchers have suggested that even more strin-
gent criteria be adopted to deﬁne HER2-positive status. Moeder
and coworkers argue that, for IHC, a cutoff of more than the 30%
of HER2-staining tumor cells currently recommended by ASCO/
CAP is appropriate [59]. They found that a high minimum score
for HER2 immunostaining is the most prognostic and predictive
of outcome (rather than a high maximum or average score), imply-
ing that a high cutoff should be used as the lower threshold for
immunostaining on IHC [59]. However, these suggestions are not
based on clinical or patient outcome data and cannot, therefore,
be recommended at this time.
Future directions
Over the last 15 years, the number of testing kits available for
HER2 testing has increased, and the accuracy and reproducibility
of these assays has improved. Moving forward, we face an intrigu-
ing question: do we continue to focus our efforts on improving
existing HER2 testing methodologies, or should we move toward
the development of better tests for selecting beneﬁt from HER2-di-
rected therapies? The answer to this question is probably ‘‘both,’’
but with more of a focus on the latter than the former.
The determination of HER2 status may be simpliﬁed by serum
testing, if a reliable test can be developed. Potential candidates
for such a test are soluble HER2 (sHER2) extracellular domainbreast cancer by FDA criteria but not by ASCO/CAP (2007) criteria (gray lines) and in
icates that the HR was calculated without stratifying for hormone receptor status or
zumab beneﬁt in N9831 patients using the ASCO/CAP HER2-positivity criteria. J Natl
plus cyclophosphamide; ASCO, American Society of Clinical Oncology; CAP, College
inistration; HR, hazard ratio.
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ECD can be accurately quantiﬁed in serum using an enzyme-linked
immunosorbent assay, which is relatively quick and simple com-
pared with IHC and FISH [60]. In the NCCTG N9831 trial, high base-
line sHER2 ECD levels were found to predict poor prognosis;
however, data do not yet support use of this assay as a primary
diagnostic screen [61]. HER2 levels in CTCs can be detected using
a two-step process that involves enrichment and identiﬁcation
[62]. HER2-positive CTCs do not necessarily reﬂect the HER2 status
of the primary tumor [63], but may reﬂect the status of potential
metastatic deposits [62]. Current data are inconsistent regarding
the role of HER2-positive CTCs in predicting treatment response
[62].
HER2 gene ampliﬁcation is intrinsically linked to mRNA overex-
pression, therefore the utility of quantitative real-time polymerase
chain reaction (RT-PCR) has been assessed as a potential alterna-
tive to IHC and FISH. Quantitative RT-PCR may improve the sim-
plicity or accuracy of HER2 testing and has some advantages over
current methods; it is quantitative, does not require ‘‘trained eyes’’
to interpret, is not subject to interobserver variability and can be
standardized, automated and performed on small samples
[64,65]. However, during RNA extraction for RT-PCR, tumor cells
and non-tumor cells are mixed, which can dilute the inﬂuence of
the tumor cells on the result, leading to false-negative ﬁndings
[64,65]. Currently, data on the accuracy of quantitative RT-PCR rel-
ative to IHC or FISH methods are variable, with some studies meet-
ing the concordance threshold of 95% set by ASCO/CAP [64,66–69]
and others showing lower levels of concordance [70,71].
While RT-PCR appears to be very speciﬁc [65,68,69], concern
has been raised regarding the test’s sensitivity [72], with reports
of high rates of equivocal ﬁndings and false-negative results that
could lead to mismanagement of patients [67,69]. Based on data
available to date, high concordance between RT-PCR and IHC/FISH
is possible, but there is insufﬁcient evidence to justify using RT-
PCR as the optimal method to make decisions for use of anti-
HER2 therapies [72]. Another mRNA technique has recently been
reported, using automated direct quantiﬁcation of HER2 mRNA
by in situ hybridization [73]. Because this technique measures
mRNA at the single-cell level in intact tissue slices, it sidesteps
problems that can lead to equivocal results in RT-PCR, such as tu-
mor heterogeneity or mixing of tumor and non-tumor cells during
sample preparation. The method’s lack of reliance on a reference
gene removes another potential source of variability.
Limited information about the predictive value of HER2 mRNA
for outcomes in patients with breast cancer is currently available.
An analysis of data from the GeparTrio study demonstrated that
HER2 status determined by RT-PCR was predictive of pathological
complete response to neoadjuvant chemotherapy with anthracy-
clines and taxanes on univariate, but not multivariate, analysis,
whereas centrally determined HER2 status using IHC and/or SISH
was predictive of response in both [66]. Further analyses are
underway, including one using Oncotype DX to examine the rela-
tionship between HER2 mRNA expression levels and beneﬁt from
trastuzumab in the NCCTG N9831 study.
Utilizing tumor molecular signatures may lead to improve-
ments in diagnosis, recurrence prediction, and individualized
treatment strategies. Preliminary data towards a predictive model
were recently obtained using the complementary DNA-mediated
Annealing, extension, Selection, and Ligation (DASL) assay (Illu-
mina; San Diego, CA), a gene-expression proﬁling system suitable
for use with degraded RNAs. Using tumor samples from the NCCTG
N9831 trial, transcriptome modeling of 353 probes associated with
relapse-free survival (RFS; p < 0.01) in the chemotherapy-plus-con-
current-trastuzumab arm deﬁned 20 functional processes for these
genes [74]. Higher expression of 32 of the 353 genes was signiﬁ-
cantly associated with RFS at the p < 0.001 level; 27 with longerRFS and ﬁve with shorter RFS. The 27 genes associated with longer
RFS were enriched for functions in receptor signaling, chromatin
structure and transcription, control of cell death, cell cycle, Wnt/
beta-catenin signaling, and lipid signaling [74].Conclusion
The ASCO/CAP guidelines of 2007 were an important step to-
wards standardizing the methodology for HER2 status determina-
tion in breast cancer, and many laboratories have made signiﬁcant
advances in implementing the procedural recommendations [52].
However, the difference between 2007 ASCO/CAP criteria and
FDA criteria for HER2-positive status can complicate decision mak-
ing, particularly in view of recent data suggesting the possibility
that some patients who would no longer be eligible for HER2-tar-
geted therapy under ASCO/CAP criteria may still experience clinical
beneﬁt from HER2-targeted therapy. ASCO/CAP are currently
reviewing and updating their guidelines in an effort to optimize
HER2 testing and interpretation. Such guidelines are critical to en-
sure optimal patient care, as is ongoing research into reﬁning and
developing the analytical techniques required to accurately assess
HER2 status. Both aspects of improving testing should, however, be
supported by the development of a robust external quality assess-
ment/assurance scheme to monitor, in real time, the quality of
diagnostic testing for HER2 status, upon which critical treatment
decisions are made.Conﬂict of interest statement
Dr. Perez has no conﬂicts of interest to disclose; Dr. Cortes has
declared serving on Speakers’ Bureaus for Roche, Novartis, Celgene,
and Eisai, and provides consulting/advisory services to Roche, Nov-
artis, and Celgene; Dr. Gonzalez-Angulo has declared research
funding from Genentech, Novartis, Celgene, Bristol-Myers Squibb,
GlaxoSmithKline, and X-covery, and provides consulting services
for Genentech, Novartis, Celgene, Pieris, and Bayer; Dr. Bartlett is
a member of the American Society of Clinical Oncology/College of
American Pathologists (ASCO/CAP) Guideline Panel.Authorship contribution
Conception and design of the study: N/A (review article). Draft-
ing the article: Edith A. Perez. Revising the manuscript critically for
important intellectual content: Edith A. Perez, Javier Cortés, Ana
Maria Gonzalez-Angulo, John M.S. Bartlett. Final approval of the
manuscript: Edith A. Perez, Javier Cortés, Ana Maria Gonzalez-Ang-
ulo, John M.S. Bartlett.
Acknowledgment
Support for third-party writing assistance was provided by
Genentech, Inc.
References
[1] Ross JS, Slodkowska EA, Symmans WF, et al. The HER-2 receptor and breast
cancer: ten years of targeted anti-HER-2 therapy and personalized medicine.
Oncologist 2009;14:320–68.
[2] Dawood S, Broglio K, Buzdar AU, et al. Prognosis of women with metastatic
breast cancer by HER2 status and trastuzumab treatment: an institutional-
based review. J Clin Oncol 2010;28:92–8.
[3] Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of
relapse and survival with ampliﬁcation of the HER-2/neu oncogene. Science
1987;235:177–82.
[4] Seshadri R, Firgaira FA, Horsfall DJ, et al. Clinical signiﬁcance of HER-2/neu
oncogene ampliﬁcation in primary breast cancer. The South Australian Breast
Cancer Study Group. J Clin Oncol 1993;11:1936–42.
E.A. Perez et al. / Cancer Treatment Reviews 40 (2014) 276–284 283[5] Gabos Z, Sinha R, Hanson J, et al. Prognostic signiﬁcance of human epidermal
growth factor receptor positivity for the development of brain metastasis after
newly diagnosed breast cancer. J Clin Oncol 2006;24:5658–63.
[6] Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efﬁcacy and
safety of humanized anti-HER2 monoclonal antibody in women who have
HER2-overexpressing metastatic breast cancer that has progressed after
chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639–48.
[7] Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a
monoclonal antibody against HER2 for metastatic breast cancer that
overexpresses HER2. N Engl J Med 2001;344:783–92.
[8] Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after
adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med
2005;353:1659–72.
[9] Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant
chemotherapy for operable HER2-positive breast cancer. N Engl J Med
2005;353:1673–84.
[10] Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-
positive advanced breast cancer. N Engl J Med 2006;355:2733–43.
[11] Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-
positive breast cancer. N Engl J Med 2011;365:1273–83.
[12] Baselga J, Cortés J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel
for metastatic breast cancer. N Engl J Med 2012;366:109–19.
[13] Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive
advanced breast cancer. N Engl J Med 2012;367:1783–91.
[14] Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical
Oncology/College of American Pathologists. American Society of Clinical
Oncology/College of American Pathologists guideline recommendations for
human epidermal growth factor receptor 2 testing in breast cancer. Arch
Pathol Lab Med 2007;131:18–43.
[15] Food and Drug Administration. In vitro companion diagnostics devices,
<http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/
InVitroDiagnostics/ucm301431.htm>; 2013 [accessed 15.04.2013].
[16] Dako. HercepTest working procedure, 5th ed. <http://www.dako.com/us/
download.pdf?objectid=121052005>; 2013 [accessed 19.03.2013].
[17] Ventana Medical Systems. PATHWAY Anti-HER-2/neu (4B5) rabbit
monoclonal antibody package insert, revision F. <http://productlibrary.
ventanamed.com/ventana_portal/
OpenOverlayServlet?launchIndex=1&objectId=790-299114427US>; 2013
[accessed 15.03.2013].
[18] Press MF, Slamon DJ, Flom KJ, et al. Evaluation of HER-2/neu gene
ampliﬁcation and overexpression: comparison of frequently used assay
methods in a molecularly characterized cohort of breast cancer specimens. J
Clin Oncol 2002;20:3095–105.
[19] Shah S, Chen B. Testing for HER2 in breast cancer: a continuing evolution.
Pathol Res Int 2010;2011:903202. http://dx.doi.org/10.4061/2011/903202.
[20] Powell WC, Hicks DG, Prescott N, et al. A new rabbit monoclonal antibody
(4B5) for the immunohistochemical (IHC) determination of the HER2 status in
breast cancer: comparison with CB11, ﬂuorescence in situ hybridization
(FISH), and interlaboratory reproducibility. Appl Immunohistochem Mol
Morphol 2007;15:94–102.
[21] Dybdal N, Leiberman G, Anderson S, et al. Determination of HER2 gene
ampliﬁcation by ﬂuorescence in situ hybridization and concordance with the
clinical trials immunohistochemical assay in women with metastatic breast
cancer evaluated for treatment with trastuzumab. Breast Cancer Res Treat
2005;93:3–11.
[22] Perez EA, Press MF, Dueck AC, et al. Immunohistochemistry and ﬂuorescence
in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy
for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005). Breast Cancer
Res Treat 2013;138:99–108.
[23] Penault-Llorca F, Bilous M, Dowsett M, et al. Emerging technologies for
assessing HER2 ampliﬁcation. Am J Clin Pathol 2009;132:539–48.
[24] Isola J, Tanner M, Forsyth A, et al. Interlaboratory comparison of HER-2
oncogene ampliﬁcation as detected by chromogenic and ﬂuorescence in situ
hybridization. Clin Cancer Res 2004;10:4793–8.
[25] Saez A, Andreu FJ, Segui MA, et al. HER-2 gene ampliﬁcation by chromogenic
in situ hybridisation (CISH) compared with ﬂuorescence in situ hybridisation
(FISH) in breast cancer–a study of two hundred cases. Breast 2006;15:519–27.
[26] van de Vijver M, Bilous M, Hanna W, et al. Chromogenic in situ hybridisation
for the assessment of HER2 status in breast cancer: an international validation
ring study. Breast Cancer Res 2007;9:R68.
[27] Francis GD, Jones MA, Beadle GF, et al. Bright-ﬁeld in situ hybridization for
HER2 gene ampliﬁcation in breast cancer using tissue microarrays: correlation
between chromogenic (CISH) and automated silver-enhanced (SISH) methods
with patient outcome. Diagn Mol Pathol 2009;18:88–95.
[28] Bartlett JMS, Campbell FM, Ibrahim M, et al. A UK NEQAS ISH multicenter ring
study using the Ventana HER2 dual-color ISH assay. Am J Clin Pathol
2011;135:157–62.
[29] Tubbs R, Loftin I, Wang L, et al. Dual color dual hapten HER2 genotyping for
breast biopsy specimens (DDISH): concordance with ﬂuorescence in situ
hybridization (FISH). San Francisco (CA): Poster presented at the 2009
American Society for Clinical Oncologists Breast Cancer Symposium, October
8-10; 2009 [Abstract 73].
[30] Bartlett JMS, Starczynski J, Atkey N, et al. HER2 testing in the UK:
recommendations for breast and gastric in-situ hybridisation methods. J Clin
Pathol 2011;64:649–53.[31] Leong TY, Cooper K, Leong AS. Immunohistology – past, present, and future.
Adv Anat Pathol 2010;17:404–18.
[32] Mohsin SK. HER2 testing: state of the laboratories. Arch Pathol Lab Med
2010;134:660–2.
[33] Walker RA. Quantiﬁcation of immunohistochemistry – issues concerning
methods, utility and semiquantitative assessment I. Histopathology
2006;49:406–10.
[34] Vance GH, Barry TS, Bloom KJ, et al. Genetic heterogeneity in HER2 testing in
breast cancer: panel summary and guidelines. Arch Pathol Lab Med
2009;133:611–2.
[35] Bartlett AI, Starcyznski J, Robson T, et al. Heterogeneous HER2 gene
ampliﬁcation: impact on patient outcome and a clinically relevant
deﬁnition. Am J Clin Pathol 2011;136:266–74.
[36] Lee S, Jung W, Hong SW, et al. Evaluation of intratumoral HER-2 heterogeneity
by ﬂuorescence in situ hybridization in invasive breast cancer: a single
institution study. J Korean Med Sci 2011;26:1001–6.
[37] Ohlschlegel C, Zahel K, Kradolfer D, et al. HER2 genetic heterogeneity in breast
carcinoma. J Clin Pathol 2011;64:1112–6.
[38] Starczynski J, Atkey N, Connelly Y, et al. HER2 gene ampliﬁcation in breast
cancer: a rogues’ gallery of challenging diagnostic cases: UKNEQAS
interpretation guidelines and research recommendations. Am J Clin Pathol
2012;137:595–605.
[39] Wu JM, Halushka MK, Argani P. Intratumoral heterogeneity of HER-2 gene
ampliﬁcation and protein overexpression in breast cancer. Human Pathol
2010;41:914–7.
[40] Simon R, Nocito A, Hubscher T, et al. Patterns of her-2/neu ampliﬁcation and
overexpression in primary and metastatic breast cancer. J Natl Cancer Inst
2001;93:1141–6.
[41] Regitnig P, Schippinger W, Lindbauer M, et al. Change of HER-2/neu status in a
subset of distant metastases from breast carcinomas. J Pathol
2004;203:918–26.
[42] Zidan J, Dashkovsky I, Stayerman C, et al. Comparison of HER-2 overexpression
in primary breast cancer and metastatic sites and its effect on biological
targeting therapy of metastatic disease. Br J Cancer 2005;93:552–6.
[43] Tapia C, Savic S, Wagner U, et al. HER2 gene status in primary breast cancers
and matched distant metastases. Breast Cancer Res 2007;9:R31.
[44] Paik S, Bryant J, Tan-Chiu E, et al. Real-world performance of HER2 testing –
National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer
Inst 2002;94:852–4.
[45] Roche PC, Suman VJ, Jenkins RB, et al. Concordance between local and central
laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst
2002;94:855–7.
[46] Perez EA, Suman VJ, Davidson NE, et al. HER2 testing by local, central, and
reference laboratories in specimens from the North Central Cancer Treatment
Group N9831 intergroup adjuvant trial. J Clin Oncol 2006;24:3032–8.
[47] Vogel CL, Bloom K, Burris H, et al. Discordance between central and local
laboratory HER2 testing from a large HER2-negative population in VIRGO, a
metastatic breast cancer registry. Cancer Res 2011;71(Suppl. 24):188s
[Abstract P1–07-02].
[48] Walker RA, Bartlett JM, Dowsett M, et al. HER2 testing in the UK: further
update to recommendations. J Clin Pathol 2008;61:818–24.
[49] ASCO/CAP. Summary of ASCO/CAP HER2 guideline recommendations, <http://
www.cap.org/apps/docs/committees/immunohistochemistry/
summary_of_recommendations.pdf>; 2013 [accessed 15.04.2013].
[50] Nakhleh RE, Grimm EE, Idowu MO, et al. Laboratory compliance with the
American Society of Clinical Oncology/College of American Pathologists
guidelines for human epidermal growth factor receptor 2 testing: a College
of American Pathologists survey of 757 laboratories. Arch Pathol Lab Med
2010;134:728–34.
[51] Hameed O, Adams AL, Baker AC, et al. Using a higher cutoff for the percentage
of HER2+ cells decreases interobserver variability in the interpretation of HER2
immunohistochemical analysis. Am J Clin Pathol 2008;130:425–7.
[52] Brunelli M, Manfrin E, Martignoni G, et al. HER-2/neu assessment in breast
cancer using the original FDA and new ASCO/CAP guideline recommendations:
impact on selecting patients for herceptin therapy. Am J Clin Pathol
2008;129:907–11.
[53] Middleton LP, Price KM, Puig P, et al. Implementation of American Society of
Clinical Oncology/College of American Pathologists HER2 Guideline
Recommendations in a tertiary care facility increases HER2
immunohistochemistry and ﬂuorescence in situ hybridization concordance
and decreases the number of inconclusive cases. Arch Pathol Lab Med
2009;133:775–80.
[54] Liu YH, Xu FP, Rao JY, et al. Justiﬁcation of the change from 10% to 30% for the
immunohistochemical HER2 scoring criterion in breast cancer. Am J Clin
Pathol 2009;132:74–9.
[55] Striebel JM, Bhargava R, Horbinski C, et al. The equivocally ampliﬁed HER2
FISH result on breast core biopsy: indications for further sampling do affect
patient management. Am J Clin Pathol 2008;129:383–90.
[56] Perez EA, Dueck AC, McCullough AE, et al. Predictability of adjuvant
trastuzumab beneﬁt in N9831 patients using the ASCO/CAP HER2-positivity
criteria. J Natl Cancer Inst 2012;104:159–62.
[57] Chibon F, de Mascarel I, Sierankowski G, et al. Prediction of HER2 gene status
in Her2 2+ invasive breast cancer: a study of 108 cases comparing ASCO/CAP
and FDA recommendations. Mod Pathol 2009;22:403–9.
284 E.A. Perez et al. / Cancer Treatment Reviews 40 (2014) 276–284[58] Jensen KC, Turbin DA, Leung S, et al. New cutpoints to identify increased HER2
copy number: analysis of a large, population-based cohort with long-term
follow-up. Breast Cancer Res Treat 2008;112:453–9.
[59] Moeder CB, Giltnane JM, Harigopal M, et al. Quantitative justiﬁcation of the
change from 10% to 30% for human epidermal growth factor receptor 2 scoring
in the American Society of Clinical Oncology/College of American Pathologists
guidelines: tumor heterogeneity in breast cancer and its implications for tissue
microarray based assessment of outcome. J Clin Oncol 2007;25:5418–25.
[60] Leyland-Jones B, Smith BR. Serum HER2 testing in patients with HER2-positive
breast cancer: the death knell tolls. Lancet Oncol 2011;12:286–95.
[61] Moreno-Aspitia A, Hillman DW, Dueck AC, et al. Baseline and recurrence levels
of soluble HER2 (sHER2) in early-stage HER2-neu positive breast cancer
(HER2+BC) from the NCCTG adjuvant Intergroup trial N9831. J Clin Oncol
2009;27(Suppl. 15) [Abstract 539].
[62] Graves H, Czerniecki BJ. Circulating tumor cells in breast cancer patients: an
evolving role in patient prognosis and disease progression. Pathol Res Int
2011;2011:621090.
[63] Cao S, Li Y, Li J, et al. Quantitative determination of HER2 expression by
confocal microscopy assay in CTCs of breast cancer. Oncol Rep 2010;23:423–8.
[64] De P, Smith BR, Leyland-Jones B. Human epidermal growth factor receptor 2
testing: where are we? J Clin Oncol 2010;28:4289–92.
[65] Lehmann-Che J, Amira-Bouhidel F, Turpin E, et al. Immunohistochemical and
molecular analyses of HER2 status in breast cancers are highly concordant and
complementary approaches. Br J Cancer 2011;104:1739–46.
[66] Noske A, Loibl S, Darb-Esfahani S, et al. Comparison of different approaches for
assessment of HER2 expression on protein and mRNA level: prediction of
chemotherapy response in the neoadjuvant GeparTrio trial (NCT005544765).
Breast Cancer Res Treat 2011;126:109–17.[67] Baehner FL, Achacoso N, Maddala T, et al. Human epidermal growth factor
receptor 2 assessment in case-control study: comparison of ﬂuorescence
in situ hybridization and quantitative reverse transcription polymerase chain
reaction performed by central laboratories. J Clin Oncol 2010;28:4300–6.
[68] Susini T, Bussani C, Marini G, et al. Preoperative assessment of HER-2/neu
status in breast carcinoma: the role of quantitative real-time PCR on core-
biopsy specimens. Gynecol Oncol 2010;116:234–9.
[69] Dabbs DJ, Klein ME, Mohsin SK, et al. High false-negative rate of HER2
quantitative reverse transcription polymerase chain reaction of the Oncotype
DX test: an independent quality assurance study. J Clin Oncol
2011;29:4279–85.
[70] Nistor A, Watson PH, Pettigrew N, et al. Real-time PCR complements
immunohistochemistry in the determination of HER-2/neu status in breast
cancer. BMC Clin Pathol 2006;6:2.
[71] Cuadros M, Talavera P, López FJ, et al. Real-time RT-PCR analysis for evaluating
the Her2/neu status in breast cancer. Pathobiology 2010;77:38–45.
[72] Bartlett JMS, Starczynski J. Quantitative reverse transcriptase polymerase
chain reaction and the Oncotype DX test for assessment of human epidermal
growth factor receptor 2 status: time to reﬂect again? J Clin Oncol
2011;29:4219–21.
[73] Wang Z, Portier BP, Gruver AM, et al. Automated quantitative RNA in situ
hybridization for resolution of equivocal and heterogeneous ERBB2 (HER2).
Status in invasive breast carcinoma. J Mol Diagn 2013;15:210–9.
[74] Perez EA, Eckel-Passow JE, Ballman KV, et al. Predictive genomic markers to
chemotherapy and adjuvant trastuzumab via whole genome expression DASL
proﬁling in the N9831 adjuvant study. Cancer Res 2012;72(Suppl. 24)
[Abstract PD10-04].
